Alirocumab

Introduction Overview

Generic Name

alirocumab

Brand Name

Praluent

Dosage Form

Prefilled pen (autoinjector) for subcutaneous use

Drug Class

PCSK9 inhibitors

Pharmacokinetics

Absorption:
Alirocumab is administered via subcutaneous injection and exhibits moderate bioavailability due to first-pass lymphatic degradation typically associated with monoclonal antibodies. Absorption is relatively slow, with peak plasma concentrations observed approximately 3 to 7 days post-injection. The pharmacokinetics are linear within the recommended dosing range. Factors such as injection site (abdomen, thigh, or upper arm) can have minor effects on absorption rates but are not clinically significant. Clinical studies have confirmed consistent absorption profiles in adults and pediatric patients (aged 8 years and older).

Distribution:
Alirocumab, being a large monoclonal antibody, distributes primarily within the vascular and interstitial compartments. The volume of distribution approximates plasma volume due to its size (~150 kDa) which restricts passage across cell membranes. Alirocumab binds specifically to circulating PCSK9 and forms complexes that are then cleared. It does not cross the blood-brain barrier. Binding to the target antigen may influence distribution, resulting in target-mediated drug disposition, especially at lower doses where target binding sites are not saturated.

Metabolism:
Alirocumab is metabolized via proteolytic degradation into small peptides and amino acids by ubiquitous proteases throughout the body, typical of immunoglobulin G (IgG) monoclonal antibodies. It is not metabolized by CYP450 enzymes, minimizing potential hepatic metabolism drug interactions. The metabolism does not produce active metabolites. Clearance involves both linear (non-target-mediated) catabolism and nonlinear, target-mediated elimination related to PCSK9 binding.

Elimination:
The elimination half-life of alirocumab ranges from approximately 17 to 20 days, consistent with IgG monoclonal antibodies. Clearance occurs primarily through proteolytic catabolism following uptake by the reticuloendothelial system and target-mediated internalization upon binding to PCSK9. The elimination is dose-dependent, with higher doses saturating PCSK9 binding and resulting in more predictable, linear clearance. Renal and hepatic impairments have limited effect on elimination since catabolism is not dependent on renal or hepatic excretory function. This pharmacokinetic profile supports dosing every 2 or 4 weeks.

Dosage Forms

Available Dosage Forms:
- Prefilled pen (autoinjector) for subcutaneous injection.
- Available strengths: 75 mg/mL and 150 mg/mL.
- Pre-filled syringes of 75 mg/mL and 150 mg/mL were previously available but are now discontinued.

Dosages for Adults and Adolescents:
- Recommended starting dose for adults with hyperlipidemia or heterozygous familial hypercholesterolemia (HeFH): 75 mg SC every 2 weeks or 300 mg SC once every 4 weeks (via two separate 150 mg injections).
- Dose may be increased to a maximum of 150 mg SC every 2 weeks if LDL-C goals are not achieved.
- For adults with HeFH undergoing LDL apheresis, dose is 150 mg SC every 2 weeks, administered regardless of apheresis timing.
- Pediatric patients (aged 8 years and older) with HeFH may use dosing regimens under supervision.

Specific Patient Populations:
- Pediatric: Praluent is indicated for children aged 8 years and older with HeFH; administration should be by or under adult supervision, with children aged 8 to 11 requiring caregiver administration.
- No dosage adjustments required for renal or hepatic impairment given clearance via proteolytic catabolism.
- Elderly patients metabolize and clear Praluent similarly to younger adults, so no dose adjustment is generally necessary.
- Dose adjustments are based on LDL-C response rather than specific demographic factors.

Clinical Guidelines Suggest:
- Begin with conservative dosing and titrate based on lipid panel measurements performed prior to dosing to optimize LDL-C lowering.
- Follow regular blood testing to monitor treatment efficacy and safety.
- Injection sites: upper thigh, abdomen (avoiding a 2-inch radius around the navel), or outer upper arm (if administered by caregiver).
- Single-use only; pens should be properly discarded after one use in approved sharps containers.

Mechanism Of Action

Praluent (alirocumab) is a fully human monoclonal antibody that specifically inhibits proprotein convertase subtilisin kexin type 9 (PCSK9), a serine protease that plays a pivotal role in cholesterol homeostasis. PCSK9 binds to low-density lipoprotein receptors (LDL-R) on the surface of hepatocytes, leading to their degradation in lysosomes rather than recycling back to the cell surface. This diminishes LDL-R density and reduces the liver's capacity to clear LDL cholesterol (LDL-C) from the circulation.

By binding PCSK9 with high affinity, alirocumab prevents its interaction with LDL receptors, thereby increasing recycling and surface expression of LDL-R on hepatocytes. This results in enhanced clearance of circulating LDL-C, effectively lowering plasma LDL cholesterol levels. The mechanism addresses genetic or acquired conditions characterized by elevated LDL-C and insufficient receptor function.

At the molecular level, alirocumab's blockade of PCSK9 leads to a durable upregulation of LDL-R, demonstrated in clinical trials with significant dose-dependent LDL-C reduction, often by 50% or more when used in conjunction with statins. This action contributes to decreased plaque formation and a reduction in cardiovascular events, validating the drug's clinical benefit.

Compared to other lipid-lowering agents such as statins, which inhibit cholesterol synthesis and simultaneously increase PCSK9 expression, Praluent provides an adjunct or alternative pathway by directly neutralizing PCSK9. Unlike statins and ezetimibe, PCSK9 inhibitors offer a target-specific mechanism with minimal off-target effects. Clinical evidence supports that combining PCSK9 inhibitors with established therapies yields additive LDL-C lowering and improved clinical outcomes.

Research data from phase 3 trials including ODYSSEY program have validated the efficacy and safety of Praluent in diverse populations, elucidating its role in primary hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, as well as in secondary prevention of cardiovascular disease. Ongoing studies continue to explore long-term effects and broader cardiovascular risk reduction.

Pharmacological Actions

Selective inhibition of PCSK9 enzyme activity.
Enhancement of LDL receptor recycling and surface expression on hepatocytes.
Significant reduction of circulating low-density lipoprotein cholesterol (LDL-C) levels.
Adjunctive lipid-lowering effects when combined with statins or other therapies.
Reduction in the risk of cardiovascular events including myocardial infarction and stroke.
Modulation of familial hypercholesterolemia by restoring LDL clearance pathways.
No direct impact on synthesis of cholesterol, but indirectly reduces plasma LDL load.
Minimal systemic enzymatic or metabolic effects due to targeted monoclonal antibody action.
Prolonged LDL-C lowering effect with biweekly or monthly dosing.
Neutralization of PCSK9-mediated LDL receptor degradation, preserving hepatic LDL uptake.

Therapeutic Or Clinical Uses

Treatment of adults with primary hyperlipidemia to reduce elevated LDL cholesterol.
Management of heterozygous familial hypercholesterolemia (HeFH) in adults and children aged 8 and above.
Adjunct therapy in homozygous familial hypercholesterolemia patients requiring additional LDL-C lowering.
Reduction of cardiovascular risk in patients with established cardiovascular disease, including history of myocardial infarction, stroke, or unstable angina.
Used alongside dietary modifications and maximally tolerated statin therapy for additive LDL-C reduction.
In patients inadequately controlled with statins or with statin intolerance.
Reduction of LDL-C in patients undergoing LDL apheresis as an adjunct therapy.
Potential to decrease atherosclerotic plaque progression by substantially lowering LDL-C.
Use in pediatric hypercholesterolemia management under specialist supervision.
Secondary prevention of major adverse cardiovascular events (MACE) in high-risk populations.

Side Or Adverse Effects

Injection site reactions including redness, swelling, itching, and pain.
Muscle pain (myalgia) and spasms.
Flu-like symptoms including malaise and fatigue.
Diarrhea and gastrointestinal discomfort.
Bruising at injection site.
Allergic reactions ranging from mild hypersensitivity to severe anaphylaxis.
Rare reports of angioedema and vasculitis.
Possible development of anti-drug antibodies though clinically nonsignificant in most cases.
Potential for hypersensitivity reactions necessitating immediate discontinuation.
Local skin irritation if injected into areas of sunburn, infection, swelling, or inflammation.
Fatigue and headache have been reported in some patients.
Rare incidents of neurocognitive effects including confusion or memory impairment have been explored but not conclusively linked.
Injection site hematoma or bruising in patients on concomitant anticoagulant therapy.
General tolerability is high with a safety profile similar to placebo in clinical trials.

Precautions

Monitor patients for hypersensitivity and allergic reactions especially after the first few doses.
Use cautiously in patients with known severe allergies to monoclonal antibodies or inactive ingredients.
Avoid injecting into inflamed, infected, or damaged skin to prevent local reactions.
Pregnancy safety has not been established; use only if potential benefits justify potential risks.
Praluent is not recommended during breastfeeding due to unknown excretion in human milk.
Counsel patients on proper injection technique and safe disposal of sharps to prevent accidental injury.
In pediatric patients, administration should be supervised and carefully trained caregivers involved.
Regular lipid monitoring required to assess efficacy and guide dosing adjustments.
Not recommended in children under 8 years due to lack of safety data.
Do not discontinue therapy abruptly without consulting healthcare provider as LDL-C may rebound.
Monitor for potential neurocognitive adverse events during long-term treatment.
Caution advised when used concomitantly with other injectable medications at the same site to avoid irritation.
Educate patients on storage conditions to maintain drug integrity.
Ensure patients inform providers about all medications to avoid unnoticed interactions.

Warnings

Risk of hypersensitivity reactions including serious allergic reactions such as anaphylaxis and angioedema requiring urgent medical attention.
Discontinue immediately if signs of hypersensitivity appear, such as rash, itching, swelling, or breathing difficulties.
Safety and efficacy in children under 8 years or those with other hyperlipidemias are not established.
Unknown risks during pregnancy; potential fetal risks cannot be excluded.
Potential immunogenicity may affect efficacy or safety though rare.
Avoid use in patients with known hypersensitivity to alirocumab or its components.
Infections or inflammatory reactions at injection sites should prompt clinical evaluation.
No significant hepatotoxicity reported but liver function monitoring advised during concurrent hepatotoxic therapies.
Avoid use if the product is discolored or contains particulate matter.
Do not shake the injection pen as it can denature the monoclonal antibody.
Limitation of use in severe uncontrolled hyperlipidemia without concomitant lipid-lowering therapy.
Patients should be cautioned against using inappropriately stored or expired pens.
Adherence to proper dosing intervals critical to maintain LDL-C lowering and cardiovascular risk reduction.
Potential for small increases in neurocognitive adverse effects under investigation; monitor accordingly.

Contraindication

Hypersensitivity to alirocumab or any of the inactive ingredients in the formulation.
Known allergy to Praluent or any monoclonal antibody component.
Patients with previous severe allergic reactions to PCSK9 inhibitors.
Should not be used during pregnancy unless clearly needed and benefit outweighs risk.
Avoid use in patients with active infections at injection sites.
Contraindicated to administer into areas of extensive skin disease or trauma.
Patients with known hypersensitivity reactions to other biologics may require caution.
Discontinue if severe hypersensitivity occurs during therapy.
Avoid in pediatric patients under 8 years due to lack of data.
Not indicated for treatment of familial lipoprotein lipase deficiency or mixed dyslipidemias without elevated LDL-C.

Drug Interactions

No significant pharmacokinetic interactions expected due to monoclonal antibody metabolism via proteolysis.
Minimal interaction potential with CYP450 substrates since alirocumab does not affect CYP enzymes.
Concomitant use with statins, ezetimibe, or other lipid-lowering therapies is common and generally safe.
No data showing alteration of antiplatelet or anticoagulant drug effects, but monitor for injection site bruising.
No known interactions with vitamins or herbal supplements; clinical vigilance advised.
No contraindications reported with commonly prescribed cardiovascular medications.
No evidence of interference with hormonal contraceptives or immunizations.
Drug metabolism or clearance does not depend on renal or hepatic pathways, minimizing concerns with organ dysfunction.
Limited data on concurrent immunosuppressive agents; use with caution due to immunomodulatory effects.
No formal interaction with other subcutaneous injectable medications; avoid injection at same site simultaneously.
Potential interference with immunogenicity testing if administered with other monoclonal antibody therapies.
No significant food interactions; administration timing relative to meals is flexible.
Patients should report all concomitant medications to healthcare providers to identify rare interactions.
No impact on medications metabolized by P-glycoprotein transporters.
No known interactions with antidiabetic or antihypertensive agents.

Preparations Of The Drug

Alirocumab is supplied as a sterile, preservative-free, single-dose prefilled pen (autoinjector) for subcutaneous injection.
Available strengths for the autoinjector are 75 mg/mL and 150 mg/mL concentrations.
Pre-filled syringes (75 mg/mL and 150 mg/mL) were previously available but have been discontinued.
Inactive ingredients include histidine, polysorbate 20, sucrose, and Water for Injection USP.
The preparation is manufactured by Regeneron Pharmaceuticals, Inc.
Stored refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light.
May be kept at room temperature up to 25°C (77°F) for a maximum of 30 days prior to use.
Should not be frozen, shaken, or exposed to extreme heat or direct sunlight to preserve protein stability.
Each pen delivers a single dose and must be disposed of properly in a puncture-proof sharps container following use.
No preservatives are present; therefore, re-use or multi-dose use is prohibited.
Instructions for use include allowing the pen to reach room temperature for 30 to 40 minutes before administration.
The formulation is free from latex and designed for ease of patient self-administration or caregiver administration.
Manufactured under sterile conditions maintaining monoclonal antibody integrity and potency.
Patents protection supports proprietary monoclonal antibody production technology.